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Background: Diabetic peripheral neuropathy (DPN) is one of the most common microvascular complications of
diabetes. Glycemic variability could be an independent risk factor for diabetes complications in addition to average
glucose. Type 2 diabetes with well-controlled glycosylated hemoglobin A1c (HbA1c) may have different terms of
glycemic variability and vascular complication consequences. The aim of the study is to investigate the relationship
between glycemic variability and DPN in type 2 diabetes with well-controlled HbA1c (HbA1c < 7.0%).
Methods: 45 type 2 diabetes with well-controlled HbA1c(HbA1c < 7.0%) and with DPN (DM/DPN group) were
recruited in the study, and 45 type 2 diabetes with well-controlled HbA1c and without DPN (DM/–DPN group) were
set as controls. The two groups were also matched for age and diabetic duration. Blood pressure, body mass index
(BMI), insulin sensitivity index (Matsuda index, ISI), total cholesterol (TC), triglyceride (TG), high density lipoprotein
cholesterol (HDLC), and low density lipoprotein cholesterol (LDLC) were tested in the two groups. And all patients were
monitored using the continuous glucose monitoring (CGM) system for consecutive 72 hours. The multiple parameters
of glycemic variability included the standard deviation of blood glucose (SDBG), mean of daily differences (MODD) and
mean amplitude of glycemic excursions (MAGE).
Results: The DM/DPN group had a greater SDBG, MODD and MAGE, when compared to the DM/–DPN group
(p < 0.05). BMI, TC, and LDLC of DM/DPN group were lower than those of DM/–DPN group (p < 0.05). The patients
with hypoglycemia were comparable between the two groups (p > 0.05). Univariate analysis showed DPN was closely
associated with BMI (OR 0.82, CI 0.72–0.94, p = 0.005), TC (OR 0.63, CI 0.42–0.93, p = 0.02), LDLC (OR 0.4, CI 0.20–0.80,
p = 0.009), SDBG (OR 2.95, CI 1.55–5.61, p = 0.001), MODD (OR 4.38, CI 1.48–12.93, p = 0.008), MAGE (OR 2.18,
CI 1.47–3.24, p < 0.001). Multivariate logistic regression analysis showed that MAGE (OR 2.05, CI 1.36–3.09, p = 0.001)
and BMI (OR 0.85, CI 0.73–0.99, p = 0.033) were significantly correlating with DPN. Glycemic variability, evaluated by
MAGE, was the most significantly independent risk factor for DPN.
Conclusions: There was a close relationship between glycemic variability evaluated by MAGE and DPN in type 2
diabetes with well-controlled HbA1c.
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Diabetic peripheral neuropathy (DPN) is one of the most
common microvascular complications of diabetes, and is
associated with foot ulceration, ampuation and significant
reduction in quality of life [1,2]. DPN affected up to 50%
of all diabetic patients with long duration of disease, and
the burden of DPN was found to be considerable [3,4].
The exact pathophysiological mechanisms of DPN in
diabetes remain elusive. The potential mechanisms are as-
sociated with a number of modifiable and nonmodifiable
risk factors, including the degree of hyperglycemia, lipid
disorders, high blood pressure, cigarette smoking, alcohol
consumption, diabetes duration, height, and so on [5-7].
For all diabetic patients, tight glycemic control is vital im-
portant for prevention and treatment of the DPN.
The glycemic disorders in diabetes are not solely limited
to fasting and postprandial hyperglycemia, but can be ex-
tended to the glycemic variability that includes both up-
ward (postprandial glucose increments) and downward
(interprandial glucose decrements) changes [8]. Current
diabetic treatments are aimed to control fasting and post-
prandial glucose levels close to the target in order to pre-
vent the development of diabetes-related complications,
with glycosylated hemoglobin A1c (HbA1c) being the
gold-standard assessment of long-term overall glycemic
control. A reasonable HbA1c level, as defined by the
American Diabetes Association(ADA), is below or around
7% [9]. In addition to HbA1c, glycemic variability could
be an independent risk factor for diabetes complications
[10,11]. Diabetic patients with target value of HbA1c may
have different terms of glycemic variability and vascular
complication consequences.
Efforts to quantify glycemic variability have relied on
intermittent glucose determinations which acquired from
the continuous glucose monitoring (CGM) system. CGM
system can detect glycemic variability in more details than
the conventional self-monitoring methods of blood glu-
cose [12,13]. Glycemic variability parameters could be cal-
culated with complex formulas designed specifically for
the CGM data.
The present study was designed to determine the relation-
ship between the relationship between glycemic variability
assessed by CGM and diabetic peripheral neuropathy in
type 2 diabetes with well-controlled HbA1c (HbA1c < 7.0%).
Materials and methods
Study subjects
Total 312 type 2 diabetes with diabetic peripheral neur-
opathy were screened and diagnosed at the inpatient de-
partment of the Second Affiliated Hospital of Nantong
University from May 2011 to June 2014. The diagnosis of
type 2 diabetes was based on the ADA diagnostic criteria
2011 [14]. The diagnosis of DPN was based on the criteria
recommended by The Toronto Diabetic Neuropathy ExpertGroup [15]. Criteria of confirmed DPN included the pres-
ence of a symptom or symptoms or a sign or signs of
neuropathy and an abnormality of nerve conduction (NC)
tests. Symptoms of DPN included decreased sensation,
positive neuropathic sensory symptoms (numbness, prick-
ling or stabbing, burning or aching pain, etc.) predomin-
antly in the toes, feet, or legs. Signs of DPN included
symmetric decrease of distal sensation or unequivocally
decreased or absent ankle reflexes. Signs were revealed
through physical examination with tools: touch sensation
was tested with a 10-g monofilament on four sites per
foot, pain sensation was tested with a pin, reflexes were
tested with a tendon hammer, and vibration sensation was
tested with a standard 128-Hz tuning fork. The neuro-
pathic deficit of non-diabetic origin (e.g., caused by per-
ipheral vascular disease, arthritis, malignancy, alcohol
abuse, vitamin B deficiency, spinal canal stenosis) was ex-
cluded through a careful medical history review, a differ-
ential test, or both.
And 45 type 2 diabetic patients with well-controlled
HbA1c (HbA1c < 7.0%) and with DPN (DM/DPN group)
were chosen and recruited for the further study. At the
same time, 45 type 2 diabetic patients with well-controlled
HbA1c and without DPN (DM/–DPN group) chosen
from outpatient were set as controls. The two groups were
also matched for age and diabetic duration. All recruited
patients had no acute complications such as diabetic
ketoacidosis, or other disorders affecting glucose metabol-
ism such as hyperthyroidism. The study was approved by
the institutional review board of the Second Affiliated
Hospital of Nantong University, with written informed
consent being obtained from all participants.
Among DM/–DPN group, 10 patients treated with insu-
lin (6 with basal insulin and 4 with pre-mixed insulin), 23
patients treated with oral hypoglycaemic agents(10 with
metformin, 5 with sulfonylureas, and 8 with sulfonylureas
and metformin), and 12 patients were on lifestyle inter-
vention. Among DM/DPN group, 17 patients treated with
insulin (8 with basal insulin and 9 with pre-mixed insulin),
23 patients treated with oral hypoglycaemic agents (8 with
metformin, 8 with sulfonylureas, and 7 with sulfonylureas
and metformin), and 5 patients were on lifestyle interven-
tion. Systolic blood pressure (SBP) ≥140 mmHg, or dia-
stolic blood pressure (DBP) ≥90 mmHg, or receiving
hypertensive treatment were considered as hypertension.
23 patients in DM/–DPN group were presented with
hypertension, and 17 patients in DM/DPN group were
presented with hypertension.
CGM in all subjects
All subjects were monitored by CGM system (Medtronic
MiniMed, Northridge, CA 91325, USA) for 72 hours.
The CGM system sensor was inserted in all subjects on
day 0 and removed on day 3. Data were downloaded and
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lected on days 1 and 2. The subjects were instructed to in-
put at least four calibration readings per day and the times
of key events. During the study, all subjects had standard
meals provided by dietary division. The total calorie intake
was 30 kcal/kg per day, with 50% carbohydrates, 15% pro-
teins, and 35% fats. The calorie distribution between
breakfast, lunch, and dinner was 20%, 40%, and 40%, re-
spectively. Three daily meals were required to consume at
time of 6:30 to 7:30, 11:30 to 12:30, and 18:00 to 19:00, re-
spectively. Patients maintained diabetic treatment as usual,
and were instructed to avoid strenuous exercise during
the CGM.
The parameters of glycemic variability included the stand-
ard deviation of blood glucose (SDBG), mean of daily differ-
ences (MODD) and mean amplitude of glycemic excursions
(MAGE) [16]. MODD that calculated from the absolute dif-
ference between paired continuous glucose monitoring
values during two successive 24 hour periods was used to
assess day-to-day glycemic variability [17]. MAGE, designed
to quantify major swings of glycemia and to exclude minor
ones, was used for assessing intra-day glycemic variability in
this study [18,19]. Additionally, hypoglycemia was defined as
a period with a CGM reading <3.9 mmol/L for at least
15 minutes with an antecedent non-hypoglycemic episode
of at least 30 minutes [20].
Insulin sensitivity index determination
After CGM, blood samples were taken at 0, 30, 60, 90 and
120 min for the measurement of plasma glucose and insulin
concentrations (glucose unit: mmol/L, insulin unit: miu/L)
during 75-g oral glucose test. Insulin sensitivity was esti-
mated using the insulin sensitivity index (ISI) of Matsuda
and DeFronzo: ISI = 10000/square root of (Ins0 ×Glu0) ×
(mean glucose ×mean insulin during OGTT) [21].
Anthropometric indices and laboratory examination
Body mass index (BMI) was calculated (kg/m2). SBP and
DBP were taken three times using a sphygmomanom-
eter and then were averaged. Capillary glucose concen-
trations were measured with Lifescan Surestep blood
glucose meter. Plasma glucose levels were measured
using the glucose oxidase method. HbA1c was mea-
sured by high performance liquid chromatography
(HPLC) with D-10 hemoglobin Testing Program (Bio-
Rad). The serum insulin assay used magnetic beads-
based enzymatic spectrofluorometric immunoassay with
automatic enzyme immunoassay apparatus (AIA360,
TOSOH). Serum glucose concentrations, total choles-
terol (TC), triglyceride (TG), high density lipoprotein
cholesterol (HDLC), low density lipoprotein cholesterol
(LDLC), and serum creatinine(Scr) were measured with
Hitachi Model 7600 Series Automatic Analyzer. Glom-
erular filtration rate(GFR) was estimated by using thereexpressed 4-variable Modification of Diet in Renal
Disease (MDRD) Study equation (eGFR = 175 × (stan-
dardized Scr) –1.154 × age–0.203 × 0.742 [if female]) [22].
Statistical analyses
Data analyses were performed using the SPSS16.0 statis-
tical software (SPSS Inc., USA). Continuous variables were
expressed as means ± standard deviation (SD) or median
(interquartile range) in the case of skewed distributions.
Categorical variables were described as frequency (per-
centage). The Student t-test was applied to compare dif-
ferences of continuous variables between the two groups,
nonparametric test (Mann–Whitney U test) was applied
to compare non-normally distributed variables between
the two groups, and Chi-squared test was applied to com-
pare categorical variables between the two groups. Two
logistic regression analysis were performed to assess the
impact of different risk factors on DPN: the univariate
analysis were performed to estimate the contribution of
clinical risk factors to DPN using the odds ratio (OR) and
95% confidence interval (CI), and the multivariate logistic
regression analysis were conducted to identify independ-
ent risk factors for DPN. The risk factors were selected by
a forward selection procedure based on increment of R2
in the multivariate logistic regression analysis. p < 0.05 was
considered to be statistically significant.
Results
Baseline characteristics in the subjects
As shown in Table 1, age, sex distribution, diabetic dur-
ation, SBP, DBP, TG, HDLC, eGFR, HbA1c, and Matsuda
ISI were comparable between DM/–DPN and DM/DPN
groups (p > 0.05). 22.2% (n = 10) treated with insulin, 51.1%
(n = 23) treated with oral hypoglycaemic agents, and 26.7%
(n = 12) was on lifestyle intervention in DM/–DPN group;
37.8% (n = 17) treated with insulin, 51.1% (n = 23) treated
with oral hypoglycaemic agents, and 11.1% (n = 12) was on
lifestyle intervention in DM/DPN group. The two groups
were comparable with regard to insulin treatment, oral
hypoglycaemic agents, lifestyle intervention and stain medi-
cation (p > 0.05). BMI, TC, and LDLC of DM/DPN group
were lower than those of DM/–DPN group (p < 0.05). The
current drinking and smoking were comparable between
the two groups (p > 0.05). The prevalence of hypertension
was 51.1% in DM/–DPN group, compared with 37.8% in
DM/DPN group (p > 0.05).
Glycemic variability in the subjects
The glycemic variability parameters from CGM data were
shown in Table 1. The DM/DPN group had a greater
SDBG (2.8 ± 0.9 vs. 2.1 ± 0.6 mmol/L, p < 0.001), MODD
(2.2 ± 0.6 vs. 1.9 ± 0.3 mmol/L, p = 0.005) and MAGE
(5.8 ± 1.6 vs. 4.5 ± 0.9 mmol/L, p < 0.001), when compared
to the DM/–DPN group. 6.7% (n = 3) in DM/–DPN group
Table 1 Comparisons of clinical variables between DM/–DPN and DM/DPN groups
DM/–DPN group DM/DPN group t / χ2 p
n 45 45 – –
Age (year) 58.7 ± 6.6 59.8 ± 8.3 0.675 0.501
Female, n (%) 24 (53.3) 20 (44.4) 0.711 0.399
Diabetic duration (year) 5.0 (2.0–8.0) 6.0 (2.0–9.0) – 0.413
Insulin treatment, n (%) 10 (22.2) 17 (37.8) 2.593 0.107
Lifestyle intervention, n (%) 12 (26.7) 5 (11.1) 3.554 0.059
Hypertension, n (%) 23 (51.1) 17 (37.8) 1.620 0.203
Stain medication, n (%) 8 (17.8) 13 (28.9) 1.553 0.213
Current drinking, n (%) 20 (44.4) 22 (48.9) 0.179 0.673
Current smoking, n (%) 17 (37.8) 20 (44.4) 0.413 0.520
BMI (kg/m2) 26.2 ± 3.9 23.9 ± 3.3 3.123 0.002
Height (m) 1.68 ± 0.07 1.66 ± 0.08 0.921 0.360
SBP (mmHg) 139 ± 18 134 ± 18 1.317 0.191
DBP (mmHg) 83 ± 12 80 ± 10 1.296 0.198
TG (mmol/L) 1.6 (1.0–2.9) 1.1 (0.8–1.9) – 0.057
TC (mmol/L) 5.0 ± 1.3 4.4 ± 1.0 2.482 0.015
HDLC (mmol/L) 1.2 ± 0.3 1.1 ± 0.3 1.815 0.073
LDLC (mmol/L) 2.7 ± 0.8 2.3 ± 0.6 2.839 0.006
eGFR (ml/min/1.73 m2) 110 ± 26 105 ± 22 0.706 0.482
Matsuda ISI 94(69–145) 110 (58–153) – 0.707
HbA1c (%) 6.4 ± 0.4 6.5 ± 0.4 1.576 0.119
Hypoglycemia, n (%) 3 (6.7) 6 (13.3) 1.111 0.292
SDBG (mmol/L) 2.1 ± 0.6 2.8 ± 0.9 3.800 <0.001
MODD (mmol/L) 1.9 ± 0.3 2.2 ± 0.6 2.873 0.005
MAGE (mmol/L) 4.5 ± 0.9 5.8 ± 1.6 2.839 <0.001
Normally distributed values in the table are given as the mean ± SD, non-normally distributed values are given as the median (25% and 75% interquartiles), and
categorical variables are given as frequency (percentage).
DM/–DPN group: well-controlled type 2 diabetes without DPN; DM/DPN group: well-controlled type 2 diabetes with DPN.
BMI: body mass index; SBP/DBP: systolic/diastolic blood pressure; TC: total cholesterol; TG: triglyceride; HDLC: high density lipoprotein cholesterol; LDLC: low
density lipoprotein cholesterol; HbA1c: glycosylated hemoglobin A1c; ISI: insulin sensitivity index; eGFR: estimated glomerular filtration rate; SDBG: standard
deviation of blood glucose; MODD: mean of daily differences; MAGE: mean amplitude of glycemic excursions.
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(n = 6) in DM/DPN group had a total of 10 hypoglycemic
events (6.7% vs. 13.3%, p > 0.05).
Relationships between multiple risk factors and DPN by
univariate and multivariate analysis
In this study, the univariate analysis showed DPN was
closely associated with BMI(OR 0.82, CI 0.72–0.94, p=
0.005), TC (OR 0.63, CI 0.42–0.93, p = 0.02), LDLC (OR 0.4,
CI 0.20–0.80, p= 0.009), SDBG (OR 2.95, CI 1.55–5.61, p=
0.001), MODD (OR 4.38, CI 1.48–12.93, p= 0.008), MAGE
(OR 2.18, CI 1.47–3.24, p < 0.001). And DPN failed to asso-
ciate with age, diabetic duration, hypertension, insulin treat-
ment, lifestyle intervention, stain medication, current
drinking, current smoking, TG, HDLC, HbA1c, eGFR,
Matsuda ISI (p > 0.05) (Table 2). Multivariate logistic regres-
sion analysis showed that MAGE(OR 2.05, CI 1.36–3.09,p= 0.001) and BMI(OR 0.85, CI 0.73–0.99, p= 0.033) were
significantly correlating with DPN(Nagelkerke R2 = 0.317)
(Table 2). Glycemic variability, evaluated by MAGE, was the
most significantly independent risk factor for DPN.
Discussion
HbA1c is not correlated with glycemic variability in well-
controlled type 2 diabetes [23], and diabetic patients with
target value of HbA1c may have different terms of glycemic
variability. Hay et al. [24] reported that excessive postpran-
dial glycemic excursions were common in well-controlled
patients with type 2 diabetes treated with a sulfonylurea
with or without metformin. Our previous study also
showed that a segment of type 2 diabetes treated with insu-
lin and with well-controlled HbA1c demonstrated elevated
glycemic excursions [25]. In the present study DPN patients
with well-controlled HbA1c showed a higher glycemic
Table 2 Relationships between multiple risk factors and DPN, by univariate and multivariate analysis
Variable Univariate analysis (OR; 95% CI) p Multivariate analysis (OR; 95% CI) p
Age (year) 1.02 (0.96–1.08) 0.497 –
Female, n (%) 1.43 (0.62–3.28) 0.400 –
Diabetic duration (year) 1.05 (0.97–1.15) 0.224 –
Insulin treatment, n (%) 2.13 (0.84–5.36) 0.111 –
Lifestyle intervention, n (%) 0.34 (0.11–1.08) 0.067 –
Hypertension, n (%) 0.58 (0.25–1.35) 0.205 –
Stain medication, n (%) 1.88 (0.69–5.11) 0.216 –
Current drinking, n (%) 1.20 (0.52–2.74) 0.673 –
Current smoking, n (%) 1.32 (0.57–3.06) 0.521 –
BMI (kg/m2) 0.82 (0.72–0.94) 0.005 0.85(0.73–0.99) 0.033
Height (m) 0.97 (0.92–1.03) 0.356 –
TG (mmol/L) 0.80 (0.62–1.04) 0.097 –
TC (mmol/L) 0.63 (0.42–0.93) 0.020 –
HDLC (mmol/L) 0.26 (0.06–1.16) 0.078 –
LDLC (mmol/L) 0.40 (0.20–0.80) 0.009 –
eGFR (ml/min/1.73 m2) 1.00 (0.98–1.01) 0.478 –
Matsuda ISI 1.04 (0.59–1.85) 0.891 –
HbA1c (%) 2.45 (0.79–7.64) 0.122 –
Hypoglycemia, n (%) 2.15 (0.50–9.21) 0.301 –
SDBG (mmol/L) 2.95 (1.55–5.61) 0.001 –
MODD (mmol/L) 4.38 (1.48–12.93) 0.008 –
MAGE (mmol/L) 2.18 (1.47–3.24) <0.001 2.05 (1.36–3.09) 0.001
Results are given as odds ratios and 95% confidence intervals (OR; 95% CI).
Nagelkerke R2 = 0.317 in multivariate analysis.
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well-controlled HbA1c and without DPN.
We also evaluated and compared the effect of the con-
trol of glycemic variability on the development of DPN
in well-controlled type 2 diabetes in the study. The re-
sults showed that there were close relationships between
glycemic variability parameters and DPN in type 2
diabetes. Several previous studies showed the fasting
plasma glucose(FPG) and HbA1c variability and the risk
of microvascular complications in diabetes [26-29], but
seldom studies showed glycemic variability accessed by
CGM and microvascular complications [30,31]. Takao
et al. [26,27] revealed that in type 2 diabetes FPG vari-
ability can predict diabetic retinopathy development and
progression independently of the mean FPG or HbA1c.
Lin et al. [28] showed annual FPG and HbA1c variability
had a strong association with diabetic nephropathy in
type 2 diabetes. Kilpatrick et al. [29] in their study
showed that variability in HbA1c added to the mean
value in predicting of retinopathy and nephropathy in
type 1 diabetes. Sartore et al. [30] showed that glycemic
variability, expressed by CGM-derived indicators of
short-lived glycemic fluctuations, was an important partof glycemic control in relation to the prevalence of dia-
betic retinopathy in both type 1 and type 2 diabetes. In a
pilot study, Oyibo et al. [31] showed patients with pain-
ful neuropathy had greater glycemic excursions and pos-
sibly poorer diabetes control, compared with patients
with painless neuropathy. Our study strengthens the evi-
dence base that glycemic variability, accessed by CGM,
is associated with microvascular complications among
type 2 diabetes. And to our knowledge, this is the first
study to document that glycemic variability accessed by
CGM may play an important role in the development of
DPN in type 2 diabetes, in spite of these patients with
well-controlled HbA1c.
In the present study multivariate regression analysis
showed that glycemic variability, evaluated by MAGE, was
the most significantly correlating with DPN (OR 2.05, CI
1.36–3.09, p = 0.001). MAGE was considered as a well-
validated index of glycemic variability in the paper of
Monnier et al. [19], and activation of the oxidative stress by
MAGE and overproduction of mitochondrial superoxide
may play an axile role in the pathogenesis of diabetic com-
plications [32,33]. Several studies had demonstrated the as-
sociation between glycemic variability evaluated by MAGE
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umented that MAGE played a significant role in vascular
endothelial dysfunction and in progression of atheroscler-
osis in type 2 diabetes. Su et al. [35] documented MAGE
was associated with the presence and severity of coronary
artery disease in type 2 diabetes. MAGE may be an import-
ant predictor of mortality and major adverse cardiac event
(MACE) in elderly patients after acute myocardial infarc-
tion (AMI) [36], and elevated admission MAGE appeared
more important than admission glucose and prior long-
term abnormal glycometabolic status in predicting 1-year
MACE in patients with AMI [37]. In our study, the close
association between MAGE and DPN(microvascular com-
plication) was documented. Increased MAGE could result
in an increased risk for both microvascular and macrovas-
cular complications.
Several variables such as obesity, increased height, pres-
ence of hypertension, antidiabetic treatment type, current
smoking and drinking, lipid disorders (such as elevated
TC, TG and LDLC), identified as predictors of DPN in
other populations [6,7], did not emerge as independent
predictors in the present study. According to our results
patients with DPN had a significantly lower BMI, TC and
LDLC, and lower BMI was the independent risk for DPN
in the multivariate regression analysis. Lean (lower BMI),
lower TC or LDLC may imply imbalance of nutrition in
patients with DPN, which may not benefit to the rehabili-
tation of DPN. And moderate BMI and balanced nutrition
may promote the rehabilitation of DPN. Lower BMI may
be a new potential independent risk factor for DPN. There
was a controversy in the relationship between insulin ther-
apy and presence of DPN. Katulanda et al. [38] showed
there was a significant association between the use of in-
sulin and presence of DPN. Pop-Busui et al. [39] showed a
glycemic control therapy with insulin-sensitizing signifi-
cantly reduced the incidence of DPN compared with
insulin-providing therapy among patients with type 2 dia-
betes followed for up to 4 years during the study. Our
study showed that presence of DPN did not associated
with insulin therapy. The reason may be that the study
populations were different in sample, ethnicity, diabetic
duration, glycemic status, and so on.
It should be pointed out that our study had some limita-
tions. First, the most obvious limitation of the study was
the cross-sectional statistical analysis, which only analyzed
the relationship between magnitude of glycemic variability
and DPN, and could not analyze long-term of glycemic
variability and DPN. Second, it needs a follow-up study to
investigate the admission MAGE in the role of the im-
provement of DPN. If the result is positive, it could further
strength the close relationship between glycemic variabil-
ity and DPN. Third, we could not assess the relationship
between oxidative stress or inflammation and glycemic
variability. Fourth, although we provided standard mealsfor patients and maintained the patients’ diabetic treat-
ment as usual during the CGM system monitoring period,
some factors, such as physical activity and emotional
stress, etc., which may affect levels of glycemic variability,
could not all be prevented.
Conclusion
In summary, DPN patients with well-controlled HbA1c
showed a higher glycemic variability, compared with well-
controlled type 2 diabetes without DPN. And glycemic
variability, evaluated by MAGE, was the significantly inde-
pendent risk factor for DPN in type 2 diabetes with well-
controlled HbA1c (HbA1c < 7.0%).
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